Vis børsmeldingen
clinical stage company focused on developing immuno-oncology therapies to target
solid tumors, announces that the European Patent Office has granted European
Patent no 3040320. The patent protects Targovax’ mutant-RAS specific neoantigen
peptides, mutant RAS specific T cells and vaccines TG01 and TG02, for the
treatment of cancer in combination with chemotherapies.
Jon Amund Eriksen, special advisor and Co-founder of Targovax, said: “We are
delighted that this European patent has been granted, further strengthening
Targovax’ intellectual property portfolio covering the very important mutant-RAS
neoantigen and mutant-RAS specific T cells. The oncology market is ever
expanding, with the immuno-oncology segment expected to see the largest growth
in the coming years. Securing this patent protects our innovative mutant-RAS
specific cancer immunotherapy platform and strengthens our market position for
treatment of RAS-mutated cancers.”
Targovax’ proprietary mutant-RAS neoantigen vaccine platform is designed to
treat patients with tumors harboring RAS mutations. Mutations in the RAS genes
are a driving cause of cancer development and progression and is linked to poor
prognosis. By inducing an anti-mutant-RAS specific immune response, TG01 and
TG02 have the potential to delay disease progression and increase survival, with
a favorable safety profile compared to chemotherapy and many other treatment
options.
In the recently completed Phase I/II clinical trial TG01-01 in resected
pancreatic cancer with TG01 treatment in combination with the chemotherapeutic
agent gemcitabine, immune response was seen in 94% (30/32) of patients. The
median survival was 33.4 months in the first cohort of 19 patients and median
survival of the second cohort of 13 is not yet reached. The median disease-free
survival was 13.9 months in the first cohort and 19.5 months in the second
cohort, comparing favorably with historical controls of patients treated with
gemcitabine alone.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: [email protected]
Simon Conway/Stephanie Cuthbert - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected]
About Targovax
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage biotechnology company developing immune
activators to target hard-to-treat solid tumors. Immuno-oncology is currently
one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect and
replicate in cancer cells. It has been shown to activate the immune system to
generate tumor-specific immune responses. In phase I trials, ONCOS-102 induced
both local and systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102’s lead indication is mesothelioma,
where the virus is currently being tested in a randomized phase II trial, with a
phase Ib safety lead-in cohort. Another trial, in advanced melanoma, is expected
to produce important proof of concept data for checkpoint inhibitor refractory
patients.
Targovax is also developing a neo-antigen cancer vaccine targeting tumors that
express mutated forms of RAS - mutations known to drive cancer. The TG vaccine
program has shown a signal of efficacy compared to historical control in a 32
-patient trial with TG01 in resected pancreatic cancer. A next generation
product candidate, TG02 is currently tested as monotherapy and will also be
tested in combination with KEYTRUDA® (an anti-PD1 check point inhibitor, CPI).
http://www.netfonds.no/quotes/release.php?id=20190117.OBI.20190117S4